<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/><meta name="exporter-version" content="Evernote Mac 7.14 (458244)"/><meta name="author" content="taylor.arhar@gmail.com"/><meta name="created" content="2020-09-17 21:58:42 +0000"/><meta name="latitude" content="37.76960833333333"/><meta name="longitude" content="-122.3920888888889"/><meta name="source" content="desktop.mac"/><meta name="updated" content="2020-09-17 22:26:13 +0000"/><title>September 17, 2020</title></head><body><div>DJB1 CTDs competition FP with FL Hsc70 and nucleotide</div><div>-GOAL: repeat the experiment performed on 082720, testing ATP vs ADP, after extensive dialysis of Hsc70</div><div>-Hsc70 was dialyzed as described in Rauch JBC 2014 (Day 1 5mM EDTA, day 2 1mM EDTA, day 3 no EDTA)</div><div>-after dialysis and concentration, Hsc70 stock was measured to be 51.20uM</div><div>-to maximize [Hsc70] in assay, 14uL of assay volume was used for Hsc70, remaining 4uL was used for all other components</div><div>-conditions: 5uM DJB1 CTDs, varying [Hsc70], 1mM nucleotide, 20nM tracer in 50mM Tris, 15mM NaCl, 1mM DTT, 0.01% Triton, pH8</div><div>-RESULTS: presence of ADP led to an increase in max mP in the presence of DJB1 CTDs (tracer only baseline for ADP was similar to that of ATP); however, there does not seem to be a significant shift in the dose curve between ATP and ADP</div><div><a href="September%2017,%202020.html.resources/091720%20DJB1%20CTDs%20competition%20FP%20FL%20Hsc70%20ATP%20vs%20ADP.pdf">091720 DJB1 CTDs competition FP FL Hsc70 ATP vs ADP.pdf</a></div><div><img src="September%2017,%202020.html.resources/IMG_4083.jpg" /></div><div><br/></div></body></html>
